查看文章

Background: Adults with diabetes and other conditions are at increased risk of severe RSV disease and hospitalization. In a phase 3 placebo-controlled study (NCT04886596) in adults≥ 60 years, RSVPreF3 OA showed 82.6% vaccine efficacy (VE) against RSV-related lower respiratory tract disease (RSV-LRTD) and 71.7% against RSV-related acute respiratory infection (RSV-ARI). We assessed VE among participants with different BMI and with selected pre-existing metabolic or endocrine conditions (eg, diabetes) that increase the risk of severe RSV disease.

Methods: Adults≥ 60 years were 1: 1 randomized to receive 1 dose of RSVPreF3 OA or placebo before the RSV season. VE against first occurrence of RSV-LRTD and RSV-ARI was calculated for different subgroups (Table).

Results: In total, 24,966 participants received RSVPreF3 OA (12,467) or placebo (12,499). Of these, 25.7%(RSVPreF3 OA) and 25.9 …